Interstitial chemotherapy with biodegradable BCNU (Gliadel) wafers in the treatment of malignant gliomas.

摘要: Malignant gliomas represent the majority of primary brain tumors, and prognosis patients afflicted with these tumors has been historically dismal, almost uniform progressive neurologic impairment rapid death. Even multimodal treatment using surgery, focal radiation, chemotherapy, no major strides were made until recently. The development interstitial BCNU wafers (carmustine wafers, Gliadel®) led to promising results in a selected malignant gliomas, as well other intracranial malignancies.BCNU is one first systemic chemotherapies which had obtained United States Food Drug Administration (FDA) approval for tumors. However, use hampered by modest prolongation survival prolonged myelosuppression potentially fatal pulmonary toxicity. therapies represented great step forward, allowing direct delivery tumor bed, virtually toxicities. Clinical studies have showed good efficacy both newly diagnosed recurrent possible therapeutic role or secondary malignancies. New are currently underway trying improve (Gliadel®) combining them different chemotherapies. An overview current knowledge ranging from preclinical developments, safety seen clinical trials practice following drug future avenues research therefore timely.